Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy

Alzheimer's and Dementia: Translational Research and Clinical Interventions

Volumn 3, Issue 3, 2017, Pages 339-347

  Landen, Jaren W ^a   Cohen, Sharon ^b   Billing, Clare B ^a   Cronenberger, Carol ^a   Styren, Scot ^a   Burstein, Aaron H ^a   Sattler, Catherine ^a   Lee, Jae Hong ^c   Jack, Clifford R ^d   Kantarci, Kejal ^d   Schwartz, Pamela F ^a   Duggan, William T ^a   Zhao, Qinying ^a   Sprenger, Ken ^a   Bednar, Martin M ^a   Binneman, Brendon ^a  

^a PFIZER INC   (United States)

^b Toronto Memory Program   (Canada)

^c Asan Medical Center   (South Korea)

^d MAYO CLINIC   (United States)

Author keywords

Alzheimer's disease; Amyloid ; Biomarkers; Cerebrospinal fluid; Immunotherapy; Monoclonal antibody; Pharmacodynamics; Pharmacokinetics; Phase II study; Ponezumab

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CHOLINESTERASE INHIBITOR; MEMANTINE; PLACEBO; PONEZUMAB; TAU PROTEIN;

ADULT; ADVERSE OUTCOME; AGED; AGGRESSION; AGITATION; ALZHEIMER DISEASE; ANXIETY DISORDER; ARTICLE; BACKACHE; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN SIZE; CEREBROSPINAL FLUID; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONFUSION; CONSTIPATION; CONTROLLED STUDY; CONTUSION; COUGHING; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INFUSION; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; FALLING; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYGROMA; HYPERTENSION; IMMUNOGENICITY; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MENINGOENCEPHALITIS; MULTIPLE DRUG DOSE; NAUSEA; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; RHINOPHARYNGITIS; SIDE EFFECT; SIDEROSIS; SUBDURAL HEMATOMA; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WEIGHT REDUCTION; WHITE MATTER LESION;

EID: 85020024076     PISSN: None     EISSN: 23528737     Source Type: Journal    
DOI: 10.1016/j.trci.2017.04.003     Document Type: Article

References (17)

1. Wippold, F.J. 2nd, Cairns, N., Vo, K., Holtzman, D.M., Morris, J.C., Neuropathology for the neuroradiologist: plaques and tangles. AJNR Am J Neuroradiol 29 (2008), 18–22.
2. McLean, C.A., Cherny, R.A., Fraser, F.W., Fuller, S.J., Smith, M.J., Beyreuther, K., et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46 (1999), 860–866.
3. Auriel, E., Greenberg, S.M., The pathophysiology and clinical presentation of cerebral amyloid angiopathy. Curr Atheroscler Rep 14 (2012), 343–350.
4. Salloway, S., Sperling, R., Fox, N.C., Blennow, K., Klunk, W., Raskind, M., et al. Two Phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. New Engl J Med 370 (2014), 322–333.
5. Doody, R.S., Thomas, R.G., Farlow, M., Iwatsubo, T., Vellas, B., Joffee, S., et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. New Engl J Med 370 (2014), 311–321.
6. Siemers, E.R., Sundell, K.L., Carlson, C., Case, M., Sethuraman, G., Liu-Seifert, H., et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer's disease patients. Alzheimers Dement 12 (2016), 110–120.
7. Liu-Seifert H, Aisen PS, Andersen SW, Holdridge KC, Siemers ER. Delayed start analyses of up to 3.5 years in the phase 3 solanezumab expedition program in mild Alzheimer's disease. Presented at the Alzheimer's Association International Conference 2015;Abstract 4769.
8. Clinicaltrials.gov. NCT01677572. Available at: https://clinicaltrials.gov/ct2/show/NCT01677572?term=aducanumab&rank=1.
9. Sevigny J, Chiao P, Williams L, Chen T, Ling Y, O'Gorman J, et al. Aducanumab (BIIB037), an anti-amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer's disease: interim results of a randomized, double-blind, placebo-controlled, Phase 1B study. Presented at the Alzheimer's Association International Conference 2015;Abstract 4484.
10. Clinicaltrials.gov. NCT02484547. Available at: https://www.clinicaltrials.gov/ct2/show?term=aducanumab&rank=3.
11. Clinicaltrials.gov. NCT02477800. Available at: https://www.clinicaltrials.gov/ct2/show?term=aducanumab&rank=4.
12. Armour, K.L., van de Winkel, J.G., Williamson, L.M., Clark, M.R., Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies. Mol Immunol 40 (2003), 585–593.
13. Wilcock, D.M., Rojiani, A., Rosenthal, A., Subbarao, S., Freeman, M.J., Gordon, M.N., et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation, 1, 2004, 24.
14. Landen, J.W., Zhao, Q., Cohen, S., Borrie, M., Woodward, M., Billing, C.B. Jr., et al. Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study. Clin Neuropharmacol 36 (2013), 14–23.
15. Burstein, A.H., Zhao, Q., Ross, J., Styren, S., Landen, J.W., Ma, W.W., et al. Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease. Clin Neuropharmacol 36 (2013), 8–13.
16. Miyoshi, I., Fujimoto, Y., Yamada, M., Abe, S., Zhao, Q., Cronenberger, C., et al. Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study. Int J Clin Pharm Ther 51 (2013), 911–923.
17. Kantarci, K., Gunter, J.L., Tosakulwong, N., Weigand, S.D., Senjem, M.S., Petersen, R.C., et al. Focal hemosiderin deposits and β-amyloid load in the ADNI cohort. Alzheimers Dement 9 (2013), S116–S123.